Abstract: Gene therapy is emerging as a potential strategy for the treatment of cardiovascular disease such as restenosis after angioplasty, vascular bypass graft occlusion, transplant coronary vasculopathy, for which no known effective therapy exists. One strategy for combating disease processes has been to target to the transcriptional process. Two approaches have been used to accomplish this. One is the use of antisense that is complimentary to the mRNA of interest. The second approach is the use of ribozymes, a unique class of RNA molecules that not only store information but also process catalytic activity. Ribozymes are known to catalytically cleave specific target RNA leading to degradation, whereas antisense inhibit translation by binding to mRNA sequences on a stoicheometric basis. Theoretically, ribozymes are more effective to inhibit target gene expression. Especially, the application of DNA technology such as antisense strategy to regulate the transcription of disease-related genes in vivo has important therapeutic potential. More recently, transfection of cis-element double stranded (ds) oligodeoxynucleotides (ODN) (= decoy) as a powerful tool in a new class of anti-gene strategies for gene therapy has been reported. Transfection of ds ODN corresponding to cis sequence will result in the attenuation of authentic cis-trans interaction, leading to the removal of trans-factors from the endogenous cis-elements with subsequent modulation of gene expression. This "decoy" strategy is not only a novel strategy for gene therapy as an anti-gene strategy, but also a powerful tool for the study of endogenous gene regulation in vivo as well as in vitro. In this review, we have focused on the future potential of oligonucleotide (antisense, decoy & ribozyme)-based gene therapy for the treatment of cardiovascular disease.
As a consequence of the developments in the field of molecular biology and their impact on our understanding of the mechanisms of disease processes, treatment strategies, which exploit our expanding knowledge of the structures and functions of molecules, are being purchased. Recent progress in molecular biology has provided new techniques to inhibit target gene expression. Especially, the application of DNA technology such as antisense strategy to regulate the transcription of disease-related genes in vivo has important therapeutic potential. Antisense oligodeoxynucleotides (ODN) are widely used as inhibitors of specific gene expression, because they offer the exciting possibility to block the expression of a particular gene without any changes in functions of other genes (see Fig. 1 ) [1] . Therefore, antisense ODN are useful tools in the study of gene function and may be potential therapeutic agents. The second approach is the use of ribozymes, a unique class of RNA molecules that not only store information but also process catalytic activity [2] . Ribozymes are known to catalytically cleave specific target RNA leading to degradation, whereas antisense inhibit translation by binding to mRNA sequences on a stoicheometric basis. Theoretically, ribozymes are more effective to inhibit target gene expression. On the other hand, more recently, we have found a novel molecular strategy in which synthetic double stranded DNA with high affinity for a target transcription factor may be introduced into target cells as a "decoy" cis element to bind the transcription factor and alter gene transcription [3] . In this article, we reviewed the potential therapeutic strategy using antisense, ribozyme and decoy for the treatment of cardiovascular disease. effectiveness of this procedure is limited by the development of restenosis in over 40 % of patients [4] . Balloon angioplasty is one of the major therapeutic approaches to coronary artery stenosis. However, restenosis occurs in 30-40 % of patients after angioplasty. Intimal hyperplasia develops in large part as a result of vascular smooth muscle cell (VSMC) proliferation and migration induced by a complex interaction of multiple growth factors that are activated by vascular "injury" [4] . The process of VSMC proliferation is dependent on the coordinated activation of a series of cell cycle regulatory genes that results in mitosis. Our previous data revealed that a single administration of antisense oligonucleotides against profileration cellular nuclear antigen (PCNA) and cdc 2 kinase genes inhibited neointimal formation after angioplasty at least up to 8 weeks after transfection [5] . In addition, a single administration of cyclin B 1 /cdc 2 antisense ODN combination significantly inhibited the extent of neointimal formation for a period of 8 weeks after transfection [6, 7] . Alternatively, the effectiveness of antisense ODN against proto-oncogenes such as c-myc and c-myb has been reported for the treatment of restenosis [8, 9] . Currently, phase II trial using antisense cmyc to treat restenosis is underway in Europe as well as United States.
ANTISENSE-BASED GENE THERAPY
proliferative vascular disease may also be an ideal target for antisense ODN-based strategy. Mann et al. reported that transfection of antisense ODN against PCNA and cdc 2 kinase resulted in the inhibition of hyperplasia at 2 weeks after transfection in vein graft model [10] . Moreover, previous gene transfer experiments showed that the prevention of neointimal formation in the balloon injury model by cell cycle inhibition strategy was sustained long term over the period of transgene expression or antisense survival [5] [6] [7] 10] . This may relate to the vascular remodeling induced by the inhibition of cell cycle progression. Indeed, administration of antisense PCNA and cdc 2 kinase ODN into a vein graft model altered the resistance to diet-induced atherogenesis [11] . In addition to the prevention of restenosis after vein graft, the inhibition of hyperplasia in transplanted hearts has also been reported by Suzuki et al. Transfection of antisense cdk2 kinase ODN resulted in a significant inhibition of VSMC growth in the transplanted hearts [12] . Importantly, they also documented a significant reduction in endothelin and ICAM gene expression by antisense cdk 2 kinase ODN [13, 14] .
RIBOZYME-BASED GENE THERAPY
Another strategy, for combating disease processes to target to the transcriptional process, is the use of ribozymes, a unique class of RNA molecules that not only store information but also Similar trials have been employed to other vascular diseases, i.e., restenosis after vein graft and vasculopathy in transplanted heart. This process catalytic activity [2] . Ribozymes are known to catalytically cleave specific target RNA leading to degradation, whereas antisense ODN inhibit translation by binding to mRNA sequences on a stoicheometric basis. Theoretically, ribozymes are more effective to inhibit target gene expression. Especially, ribozyme strategy is powerful to achieve the selective inhibition of the target gene without affecting other genes. For example, a high serum concentration of lipoprotein (a) [= Lp (a)] is a risk factor for atherosclerosis, restenosis after angioplasty, cardiac disease and stroke [15, 16] . Lipoprotein (a) consists of low-density lipoprotein with an additional protein component, apolipoprotein (a), a homologue of plasminogen [17] . Lp (a) and apolipoprotein (a) enhance proliferation of human VSMC in culture by inhibiting activation of plasminogen to plasmin, thus, blocking the proteolytic activation of transforming growth factor (TGF)-β [18] [19] [20] . Therefore, to prevent atherosclerosis induced by high Lp (a) requires a decrease in apolipoprotein (a) without any effects on plasminogen production. Antisense technology may be useful to decrease Lp (a). However, antisense technology may not be useful in this case, because of the following reasons: 1) it is difficult to select antisense sequences around ATG sites that is most commonly and effectively used as antisense sequences, since the structure of apolipoprotein (a) gene around ATG sites is completely identified to the plasminogen gene, and 2) the antisense against apolipoprotein (a) may inhibit plasminogen gene expression, in addition to apolipoprotein (a). Using ribozyme strategy, we previously provided the first evidence that Lp (a) production can be prevented by ribozyme oligonucleotides directed against apolipoprotein (a) gene independent from plasminogen production, suggesting a novel therapeutic strategy for the treatment of cardiovascular diseases related to high Lp (a) (see Fig. 2 ) [21] . The selective blockade of apolipoprotein (a) is particularly attractive since the high homology of apolipoprotein (a) to plasminogen causes difficulty in the development of drugs against Lp (a). In addition, it is better to target the common sequence of target genes among human, rat and porcine etc. for applying pre-clinical animal studies to human trial using antisense or ribozyme technology. However, it is difficult to select antisense sequences around ATG sites that is most commonly and effectively used as antisense sequences, since the structure of target gene around ATG sites may not be identified among human, rat and mice. From these points, ribozyme are more attractive than antisense despite of its unstability.
Similar to antisense strategy, application of ribozyme technology to human gene therapy may require enhancement of the efficiency of cellular uptake and the stability of ribozyme oligonucleotides, since ribozyme oligonucleotides are easily degraded by nucleases because of its RNA backbone. To overcome these issues, in the previous study, we utilized a viral protein-mediated oligonucleotides transfer technique that results in "GUU" is the cleavage site for ribozyme ON against apolipoprotein (a). In contrast, "GUU" is "GCU" at this location in plasminogen RNA, resulting in no cleavage by ribozyme ON. Underlined sequences are phosphorothioate DNA, and other sequences are phosphoribose RNA. Italic sequences in plasminogen gene are mismatched compared to apolipoprotein (a) gene. Adapted from ref. [21] . Adapted from ref. [21] . more rapid cellular uptake and a 10-fold higher transfection efficiency of oligonucleotides or plasmid DNA than lipofection or passive uptake methods [22] . In addition, ribozyme ON chemically modificated with the phosphoribose backbone of RNA to phosphorothioate could be used [23, 24] . The practical use of the ribozyme as therapy for cardiovascular disease will depend upon the development of a delivery system into the liver for long-term expression.
antisense technology as a "loss of function" approach at the transcriptional and translational levels, whereas cis-element decoy strategy is also applicable as a "loss of function" approach at the pre-transcriptional and transcriptional levels to study transcription factors.
As discussed above, the process of VSMC proliferation is dependent on the coordinated activation of a series of cell cycle regulatory genes which results in mitosis. A critical element of cell cycle progression regulation involves the complex formed by E2F, cyclin A and cdk 2 [31] . The dissociation of the transcription factor E2F from retinoblastoma (Rb) gene product is proposed to play a pivotal role in the regulation of cell proliferation by inducing a coordinated transactivation of genes involved in cell cycle regulation including c-myc, c-myb, cdc 2, PCNA and thymidine kinase [31] . Accordingly, we hypothesized that transfection of VSMC with a sufficient quantity of the decoy ODN containing the E2F cis element (consensus sequence "TTTTCGGCGC") would effectively bind E2F, prevent it from transactivating the gene expression of essential cell cycle regulatory proteins and thereby inhibit VSMC proliferation and neointimal formation (Fig. 3) . Synthesized 14-mer ds ODN containing the consensus sequence effectively competed with binding of E2F to its binding site assessed by gel mobility shift assay [27] .
DECOY-BASED GENE THERAPY
Transfection of cis-element double stranded (ds) ODN (= decoy) has been reported as a powerful tool in a new class of anti-gene strategies for gene therapy [25, 26] . Transfection of ds ODN corresponding to cis sequence will result in the attenuation of authentic cis-trans interaction, leading to the removal of trans-factors from the endogenous cis-element with subsequent modulation of gene expression (Fig. 1) . Therefore, the decoy approach may also enable us to treat diseases by modulation of endogenous transcriptional regulation. Currently, several studies have reported an application of the "decoy" ODN strategy as in vivo gene therapy [27] [28] [29] [30] . The previous studies provide evidence of an in vivo application of this novel molecular approach as a therapeutic strategy against cardiovascular disease. Many researchers employed Transfection of E2F decoy ODN into rat ballooninjured carotid arteries using HVJ-liposome method resulted in almost complete inhibition of neointimal formation at 2 weeks after balloon injury, accompanied by a reduction in mRNA of PCNA and cdc 2 kinase, but not β-actin, whereas mismatched ODN had no effect on neointimal hyperplasia [3] . Of importance, sustained inhibition of neointimal formation by a single administration of E2F decoy ODN was observed at least up to 8 weeks after the treatment. This is the first successful in vivo transfer of a decoy cis element to bind E2F, modulate gene expression, and consequently inhibit smooth muscle proliferation and vascular lesion formation as gene therapy for restenosis. Currently, we submitted the clinical protocol for E2F decoy therapy to treat restenosis after angioplasty. We will start human trial using E2F decoy early next year. In addition, in 1996, clinical application of "decoy" against E2F by Dr. Dzau in Harvard University was also approved by FDA to treat neointimal hyperplasia in vein bypass grafts which results in failure in up to 50 % of grafts within a period of 10 years. Their preliminary results revealed the successful inhibition of graft occlusion, accompanied by the selective inhibition of PCNA and c-myc expression [32] . Since E2F has been postulated to play an important role in the pathogenesis of numerous diseases, e.g. glomerulonephritis and arthritis, the development of E2F decoy strategy may provide a useful therapeutic tool for treating these proliferative diseases.
induced by NFkB binding. The necessity to block cytokine and adhesion molecule genes at more than one point to achieve maximum inhibitory effects may be due to the redundancy and complexity of the interactions of these genes.
Importantly, increased NFkB binding activity was confirmed in hearts with myocardial infarction [29] . Our previous study provided the first evidence of the feasibility of decoy strategy against NFkB in treating myocardial reperfusion injury [29] . Transfection of NFkB decoy ODN into rat coronary artery prior to LAD occlusion markedly reduced the damaged area of myocytes at 24 hours after reperfusion, whereas no difference was observed between scrambled decoy ODN-treated and untransfected rats. The therapeutic efficacy of this strategy via intra-coronary administration immediately after reperfusion, similar to the clinical situation, was also examined. NFkB decoy ODN reduced the damage of myocytes due to reperfusion in contrast to rats treated with scrambled control decoy or vehicle. The selectivity of the NFkB decoy ODN effect was confirmed further by the demonstration that reduction of myocardial damaged area was not observed in rats treated with antisense ODN directed against rat inducible nitric oxide synthase (iNOS) gene. The specificity of NFkB decoy in the inhibition of cytokine and adhesion molecule expression was also confirmed by in vitro experiments using human and rat coronary artery endothelial cells. Transfection of NFkB decoy ODN markedly inhibited the protein expression of cytokines (IL-6 and 8) and adhesion molecules (VCAM, ICAM and ELAM) in response to TNF-α stimulation in human aortic endothelial cells [38] . In contrast, the control scrambled decoy ODN failed to inhibit the induction of these protein expressions. Cell numbers after transfection were not changed, indicating that the NFkB decoy induces a specific inhibitory effect rather than nonspecific cytotoxicity.
On the other hand, the transcription factor NFκB also plays a pivotal role in the coordinated transactivation of cytokine and adhesion molecule genes whose activation has been postulated to be involved in numerous diseases, such as myocardial infarction [33] . These diseases are, importantly, potentially amenable to ODN-based gene therapy, since treatment of these diseases is extremely difficult because of the lack of effective pharmacological agents. The pathophysiology of myocardial infarction is quite complicated. Numerous cytokines including interleukin-1, 2, 6, 8 and TNF-α, to name a few, regulate this process. However, gene regulation of many cytokines is relatively simple, because the transcription factor NFkB has been reported to up-regulate these cytokines [34, 35] . Interestingly, adhesion molecules such as VCAM and ICAM are also known to be up-regulated by NFkB [36, 37] Accordingly, we hypothesize that myocardial infarction and glomerulonephritis could be prevented by the blockade of genes regulating cell inflammation --the final common pathway that is Since NFkB has been postulated to play an important role in the pathogenesis of numerous diseases, e.g. cancer and arthritis, the development of NFkB decoy strategy may provide a useful therapeutic tool for treating these diseases. Furthermore, modifications of ODN composition to prolong decoy stability in vivo and/or development of a delivery system into the cardiovascular organs/tissues will be critical to enhance potential therapeutic efficacy [39, 40] . Despite these limitations, development of this technology offers great promise as a new tool for defining biological processes and treating pathological conditions. Since an important concern regarding decoy strategy revolves around the potential inhibition of normal physiological responses, the application of decoy strategy as gene therapy may be limited to treatment of acute conditions, namely "transcription factor-driven diseases". Although few papers have reported the application of the "decoy" ODN strategy as in vivo gene therapy, this approach is particularly attractive for several reasons: 1) the potential drug targets (transcription factors) are plentiful and readily identifiable, 2) the synthesis of sequence-specific decoys is relatively simple and can be targeted to specific tissues, 3) knowledge of the exact molecular structure of the targeted transcription factor is unnecessary, and 4) decoy ODN may be more effective than antisense ODN in blocking constitutively expressed factors as well as multiple transcription factors that bind to the same cis element. Thus, "decoy" strategy, may be, useful for treating a broad range of human diseases (see Table 1 ).
endosomes after trapping. Modification of ODN pharmacokinetics by the use of HVJ-liposome complex will facilitate the potential clinical utility of the agents by: 1) allowing a shorter intraluminal incubation time to preserve organ perfusion, 2) prolonging the duration of biological action, and 3) enhancing efficacy such that the nonspecific effects of high doses of ODN can be avoided. Since the virus is inactivated by ultraviolet light, there is little potential for biological hazard by the use of this method as compared to retroviral in vivo gene transfer approach.
UNDISSOLVED ISSUES IN ODN-BASED GENE THERAPY
However, these ODN-based gene therapy still have many unsolved problems such as their short half life, low efficiency of uptake and degradation by endocytosis and nucleases. Recently, in vivo administration of antisense ODN has also been reported using peri-adventitial polymer delivery system [8] . Although this delivery system is not a practical approach for the prevention of restenosis after percutaneous transluminal angioplasty in humans, successful inhibition of neointimal formation was reported in experimental model. Therefore, currently many groups are focusing on modifications of the gel approach using a catheter delivery system. On the other hand, we have developed an efficient gene transfer method mediated by viral liposome complex [22, 40] . This delivery system also enhances the efficiency and prolongs the half life of antisense ODN in vitro and in vivo [7, 22] . HVJ-liposome method is suitable for an intraluminal molecular delivery system that has several advantages over the peri-adventitial polymer delivery approach. The HVJ-ODN method substantially increases the efficiency of uptake of ODN and appears to increase the stability of the ODN within intracellular compartments [7, 22] . HVJ is well known to cause cell fusion, and thus, the complex in the viral envelope might enter the cells directly via cell membrane-liposome membrane fusion. In contrast, direct transfer of ODN cannot avoid several unresolved problems such as 1) significant intracellular degradation via the lysosomal pathway, and 2) efflux from Regarding ODN-based strategy as gene therapy, one of the major concerns is non-specific effects, particularly those of phosphorothioate substituted ODN. This concern is not only related to antisense and decoy strategy, but also to all ODN-mediated therapy. Non-sequence-specific inhibition may operate through blockade of cell surface receptor activity or interference with other proteins [41] . At the same time, ODN containing GC dinucleotides may bring about immune activation [42] . In addition, sequence-specific binding of nontranscriptional factor proteins to ODN has been reported to result in non-specific effects of ODNbased gene therapy [43] . Moreover, Burgess et al. reported that the antiproliferative activity of c-myb and c-myc antisense ODN in VSMC is caused by a non-antisense mechanism [44] . They have found that a stretch of four contiguous guanosine (4G) residues is responsible for the sequence-specific but non-antisense antiproliferative effects of c-myb and c-myc. These issues have greatly confused the specificity of effects observed with antisense ODN therapy and will likely also be relevant to double-stranded decoy ODN therapy. To overcome these issues, careful controlled experiments must be performed to eliminate the potential non-specific effects of ODN-mediated therapy.
For gene therapy using ODN-based strategy, the toxicity of phosphorothioate ODN may also be important. Although low dosage administration does not seem to cause any toxicity, bolus infusions may be dangerous. Higher doses over prolonged periods of time may cause kidney damage, as evidenced by proteinuria and leukocytes in urine in animals [43] . Liver enzymes may also be increased in most animals treated with moderate to high doses. Several phosphorothioate ODN have been shown to cause acute hypotensive events in monkeys [45, 46] , probably due to complement activation [47] . These effects are transient, if managed appropriately, and relatively uncommon. This toxicity can be avoided by giving intravenous infusions rather than bolus injections. More recently, prolongation of prothrombin, partial thromboplastin, and bleeding times has been reported in monkeys [48] . [7] Morishita, R., Gibbons, G.H., Kaneda, Y., Ogihara, T., Dzau, V.J. Pharmacokinetics of antisense oligonucleotides (cyclin B1 and cdc 2 kinase) in the vessel wall: enhanced therapeutic utility for restenosis by HVJ-liposome method. (1994) Gene., 149, 13-19. Gene therapy in the field of cardiovascular disease would be useful for the treatment of many diseases, including the prevention of restenosis after angioplasty, myocardial infarction and rejection in heart transplantation. The first federally approved human gene therapy protocol started on 14 September, 1990 for ADA deficiency patients. Eight years since the commencement of the first trial, over 250 clinical studies of gene therapy are under investigation. In the cardiovascular field, many protocols have been approved, as shown in Table 1 . Their objectives are generally 1) to evaluate the in vivo efficacy of gene transfer method, 2) the safety of the gene transfer method, and 3) the possible therapeutic efficacy. Although there are still many unresolved issues, human gene therapy for cardiovascular disease is now a reality. Although there are still many unresolved issues in the clinical application of ODN-based strategy, its utility could be widespread as a useful tool for gene therapy in other diseases. Overall, now that gene therapy for cardiovascular disease appears to be not far from reality, it is time to take a hard look at practical issues that will determine the real clinical potential. These include 1) further innovations in gene transfer methods, 2) well defined disease targets, 3) cell-specific targeting strategies, and 4) effective and safe delivery systems. 
PROSPECTIVE IN ODN-BASED STRATEGY

